Description:
NeuroDiscovery Ltd (ASX Code NDL) is an ASX listed neurology research and development company which owns 100% of NeuroSolutions Ltd. NeuroSolutions Limited is a profitable service company, applying its broad expertise and drug discovery platforms to become a leading provider of specialised electrophysiological assays to the biopharmaceutical industry. Electrophysiology is a specialised technique which is used to record electrical activity in membranes, cells or tissues. NeuroSolutions current clients include many other established pharmaceutical and biotechnology companies.
In parallel to running its service business, the Company is also exploiting its in house technologies and expertise for its own internal R&D and has a mature pipeline of programmes underway for the treatment of pain. During 2007 the company commenced Phase I trials on its lead compound NSL-043 in partnership with Sosei Co Ltd, a listed Japanese biopharmaceutical company and also intends to commence a Phase IIa with NSL 101, the company’s 100% owned natural product.